» Articles » PMID: 28890797

Defining Patient Centricity with Patients for Patients and Caregivers: a Collaborative Endeavour

Overview
Journal BMJ Innov
Date 2017 Sep 12
PMID 28890797
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patient engagement is an essential aspect in the research/development of biopharmaceutical products and disease management. Improving the lives of patients requires a deep understanding of their medical conditions, experiences, needs and priorities. However, a consistent definition of patient centricity is lacking. A series of initiatives was conducted to define patient centricity and its important principles impacting the biopharmaceutical industry.

Methods: Interviews, questionnaires and literature reviews were conducted involving key stakeholders to initially identify issues of importance to patients, healthcare providers and payers. Subsequently, two identical workshops which included 22 patients/carers created a definition of patient centricity and the healthcare values important to patients/caregivers. Outputs were tested in a validation exercise involving patients in predominantly US (n=470) and European (n=703) patient forums.

Results: Initial research provided deeper understanding of patient needs and key topics of interest that were used to cocreate a definition of patient centricity and 10 associated principles of importance to the biopharmaceutical industry. Wider testing of these outputs among predominantly US/European patient communities confirmed their validity. Patient centricity should be defined as 'Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family'. Important principles for patients focused on education/information, cocreation, access and transparency.

Conclusions: The development of a consistent definition of patient centricity and its associated principles provides an opportunity for biopharmaceutical companies to adopt and use these as a reference point for consistent patient engagement throughout the product life cycle.

Citing Articles

Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study.

Daniels S, Nelander K, Eriksson J, Jermutus L, Saillard J, Oyesola S Contemp Clin Trials Commun. 2025; 44:101437.

PMID: 39916681 PMC: 11800087. DOI: 10.1016/j.conctc.2025.101437.


High-Fidelity Clinical Simulation to Improve a Pediatric Clinical Trial Design: Lessons Learned and Conceptualization of the Return on Investment (ROI) and Return on Engagement (ROE) Analysis.

Quintilla J, de la Gala C, Berrueco R, Claverol J, Figueres B, Bergos A Paediatr Drugs. 2024; 27(1):73-84.

PMID: 39585605 PMC: 11775067. DOI: 10.1007/s40272-024-00660-8.


Embedding patient engagement in the R&D process of a life sciences company through co-creation with a patient expert R&D board: a case study.

Jobson E, Garcia M, Sharek D, Risueno L, Arnould S, Lemoine-Andre A Res Involv Engagem. 2024; 10(1):116.

PMID: 39506875 PMC: 11539748. DOI: 10.1186/s40900-024-00631-w.


Real-world usage pattern, effectiveness and safety of oral tramadol/dexketoprofen trometamol fixed-dose combination in moderate-to-severe acute pain in Asia: a prospective, multicentre, observational study.

Ho K, Gyanwali B, Dimayuga C, Eufemio E, Bernardo E, Raju G BMJ Open. 2024; 14(10):e090926.

PMID: 39419619 PMC: 11487850. DOI: 10.1136/bmjopen-2024-090926.


Patient Involvement in the Design of an Innovative Clinical Study to Compare the Palatability of Anti-Hyperkalemia Medications.

Sondergaard H Patient Prefer Adherence. 2024; 18:1059-1064.

PMID: 38835400 PMC: 11149637. DOI: 10.2147/PPA.S445399.


References
1.
Brown M, Bussell J . Medication adherence: WHO cares?. Mayo Clin Proc. 2011; 86(4):304-14. PMC: 3068890. DOI: 10.4065/mcp.2010.0575. View

2.
Perfetto E, Burke L, Oehrlein E, Epstein R . Patient-Focused Drug Development: A New Direction for Collaboration. Med Care. 2014; 53(1):9-17. DOI: 10.1097/MLR.0000000000000273. View

3.
Muhlbacher A . Patient-centric HTA: different strokes for different folks. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(4):591-7. DOI: 10.1586/14737167.2015.1038245. View

4.
Furlong P, Bridges J, Charnas L, Fallon J, Fischer R, Flanigan K . How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. Orphanet J Rare Dis. 2015; 10:82. PMC: 4486430. DOI: 10.1186/s13023-015-0281-2. View

5.
Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G . Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action. Ther Innov Regul Sci. 2015; 49(6):929-939. PMC: 4616907. DOI: 10.1177/2168479015580384. View